[A21-69] Atezolizumab (NSCLC; first line) - Benefit assessment according to §35a Social Code Book V
Last updated 19.11.2021
Commission awarded on 21.05.2021 by the Federal Joint Committee (G-BA).
First-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) and who do not have EGFR mutant or ALK-positive NSCLC
Added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
The current version 2.0 of the dossier Assessment replaces version 1.0 published on 2021-09-01.